Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

SPORE in Leukemia

Award Number: P50CA298970
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/13/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

SPORE in Leukemia - Overall Summary The overall goal of this SPORE in Leukemia is to improve understanding of the genetic and molecular basis of myeloid leukemia and acquired resistance to treatment, and to develop novel, effective therapeutic strategies. Projects extend lab-based research discoveries, establish the potential of candidate therapeutic strategies in preclinical models, and determine therapeutic efficacy in clinical trials. Each Project will leverage the extensive scientific and clinical resources at the Dana-Farber/Harvard Cancer Center (DF/HCC) in addition to the SPORE Cores. The Projects and Cores all aim to achieve the overall goal of improved outcomes for patients with leukemia and will benefit from the considerable expertise and strengths of the team. Project 1 will assess mechanisms of resistance to Menin inhibitor treatment, identify therapeutic targets likely to synergize with Menin inhibition in overcoming resistance, and initiate clinical trials to test immunomodulatory imide drugs (IMiDs) in combination with Menin inhibition. Project 2 will investigate the therapeutic efficacy and predictors of response to PI3 kinase gamma inhibition in AML, will use mechanistic analyses to optimize combination therapies with PI3Kγ inhibition, and will assess the therapeutic role of PI3Kγ inhibition in an early phase clinical trial. Project 3 proposes studies to define gene regulatory functions of the mammalian SWI/SNF (mSWI/SNF) complex in primary leukemias, evaluate the impact of pharmacologic SMARCA4/2 ATPase inhibition as a component of AML treatment, and test the clinical impact of mSWI/SNF ATPase inhibitor combinations in a phase 1b trial. The Cores have been designed to support all Projects in translational research, such that lab-based and clinical research components of each project will interface with Core 1 for biospecimen banking and the clinical database, Core 2 for genetic studies and functional precision medicine testing, and Core 3 for statistical and computational biology guidance. The Career Enhancement Program and the Development Research Program will develop the next generation of leukemia investigators and novel scientific innovation. The proposed studies promise to improve clinical outcomes for patients with leukemia.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $2,433,959 )
2026	2026	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Centers Support Grants	000	1	8/12/2026	NEW	$2,433,959
														Subtotal = $2,433,959

Grand Total All Awards = $2,433,959

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SPORE in Leukemia

Award Number: P50CA298970

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/13/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer